<DOC>
	<DOCNO>NCT00221637</DOCNO>
	<brief_summary>The purpose study determine whether valproate effective well tolerate treatment neuropathic peripheral pain . The drug administer intravenous route follow oral route 4 week .</brief_summary>
	<brief_title>Efficacy Valproate Peripheral Neuropathic Pain</brief_title>
	<detailed_description>Background . Neuropathic peripheral pain often refractory usual analgesic . Some anticonvulsant drug may effective , often partially , always well tolerate . Valproate well-known anticonvulsant drug , moderate possible adverse event intravenous form available . Aim . The principal aim ass efficacy safety sodium Valproate peripheral neuropathic pain . Secondary aim ass effect IV oral treatment neurophysiologic measure . Design . Randomized , double-blind vs. placebo , parallel group , monocentric clinical trial . Treatments . Experimental arm : Intravenous eight-hour sodium Valproate infusion , follow four-week oral route sodium Valproate treatment . Control arm : Intravenous eight-hour placebo infusion , follow four-week oral route placebo treatment . Rescue medication allow group . Eligibility criterion . Peripheral neuropathic pain pain intensity least 40 mm visual analog scale . Outcomes . Primary outcome intensity pain visual analog scale 4 week treatment . Secondary outcome : intensity pain IV treatment ; neurophysiologic measure ( thermal threshold , RIII reflex ) ; association response IV treatment oral treatment efficacy .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>peripheral neuropathic pain sign write informed consent central neuropathic pain current past hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Neuralgia</keyword>
	<keyword>Valproate</keyword>
	<keyword>Anticonvulsant Drugs</keyword>
	<keyword>Pain Measurement</keyword>
	<keyword>Randomized Controlled Trials</keyword>
</DOC>